NASDAQ:TOCA - Tocagen Stock Price, Forecast & News

Tocagen trades on the NASDAQ under the ticker symbol "TOCA."

Tocagen Inc (NASDAQ:TOCA) issued its earnings results on Tuesday, November, 12th. The company reported ($0.78) EPS for the quarter, missing the consensus estimate of ($0.68) by $0.10. The company earned $0.01 million during the quarter, compared to the consensus estimate of $0.01 million. Tocagen had a negative return on equity of 182.15% and a negative net margin of 201,488.91%. View Tocagen's Earnings History.

Tocagen is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Tocagen.

9 brokerages have issued 1-year target prices for Tocagen's shares. Their forecasts range from $1.00 to $28.00. On average, they anticipate Tocagen's share price to reach $8.22 in the next twelve months. This suggests a possible upside of 293.3% from the stock's current price. View Analyst Price Targets for Tocagen.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tocagen in the last year. There are currently 9 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Tocagen.

Media stories about TOCA stock have been trending neutral recently, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Tocagen earned a media sentiment score of 0.4 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 9.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for Tocagen.

Tocagen saw a drop in short interest during the month of January. As of January 15th, there was short interest totalling 2,020,000 shares, a drop of 14.4% from the December 31st total of 2,360,000 shares. Based on an average daily volume of 533,200 shares, the days-to-cover ratio is currently 3.8 days. Currently, 9.2% of the company's stock are sold short. View Tocagen's Current Options Chain.

Some companies that are related to Tocagen include vTv Therapeutics (VTVT), GlycoMimetics (GLYC), Strongbridge Biopharma (SBBP), Neptune Wellness Solutions (NEPT), Northwest Biotherapeutics (NWBO), Ovid Therapeutics (OVID), ContraFect (CFRX), Tyme Technologies (TYME), OASMIA PHARMACE/ADR (OASM), Avenue Therapeutics (ATXI), Adamas Pharmaceuticals (ADMS), Mustang Bio (MBIO), Selecta Biosciences (SELB), Aptinyx (APTX) and Harrow Health (HROW).

Based on aggregate information from My MarketBeat watchlists, some companies that other Tocagen investors own include Selecta Biosciences (SELB), vTv Therapeutics (VTVT), Inovio Pharmaceuticals (INO), Nabriva Therapeutics (NBRV), VBI Vaccines (VBIV), Agile Therapeutics (AGRX), Catalyst Pharmaceuticals (CPRX), SCYNEXIS (SCYX), Zynerba Pharmaceuticals (ZYNE) and Aduro BioTech (ADRO).

(TOCA) raised $80 million in an initial public offering on Thursday, April 13th 2017. The company issued 7,300,000 shares at $10.00-$12.00 per share. Leerink Partners, Evercore ISI and Stifel served as the underwriters for the IPO.

Tocagen's stock is owned by a variety of of institutional and retail investors. Top institutional investors include State Street Corp (2.24%), Geode Capital Management LLC (1.38%), Acadian Asset Management LLC (0.90%) and Goldman Sachs Group Inc. (0.20%). Company insiders that own Tocagen stock include Faheem Hasnain, Harry E Gruber and Martin J Duvall. View Institutional Ownership Trends for Tocagen.

TOCA stock was sold by a variety of institutional investors in the last quarter, including State Street Corp and Acadian Asset Management LLC. View Insider Buying and Selling for Tocagen.

TOCA stock was purchased by a variety of institutional investors in the last quarter, including Geode Capital Management LLC and Goldman Sachs Group Inc.. Company insiders that have bought Tocagen stock in the last two years include Faheem Hasnain, Harry E Gruber and Martin J Duvall. View Insider Buying and Selling for Tocagen.

Shares of TOCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of TOCA stock can currently be purchased for approximately $2.09.

Tocagen has a market capitalization of $49.95 million and generates $18.04 million in revenue each year. The company earns $-48,960,000.00 in net income (profit) each year or ($2.44) on an earnings per share basis. Tocagen employs 77 workers across the globe.View Additional Information About Tocagen.

The official website for Tocagen is http://www.tocagen.com/.

Tocagen's mailing address is 4242 CAMPUS POINT COURT SUITE 500, SAN DIEGO CA, 92121. The company can be reached via phone at 858-412-8400 or via email at [email protected]